Announced
Financials
Tags
De-SPAC
Majority
Friendly
Private
therapeutics company
Merger
treatment development
Reverse Takeover
Domestic
United States
Single Bidder
Acquisition
Biotechnology
Failed
Synopsis
Intrinsic Medicine, a preclinical-stage therapeutics company, terminated the agreement to go public via a SPAC merger with Phoenix Biotech Acquisition in a $136m deal. “Intrinsic was encouraged by the positive feedback from prospective investors regarding the attractiveness of our novel and capital-efficient approach to developing transformative new therapeutics. We remain focused on advancing these important potential drugs and are grateful to PBAX’s team of experienced life-sciences investment veterans for recognizing the fundamental value of our platform and pipeline,” Alexander Martinez, Intrinsic CEO. On December 6, 2022 Intrinsic Medicine and Phoenix Biotech Acquisition mutually terminate the transaction.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.